[go: up one dir, main page]

MA31993B1 - Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate - Google Patents

Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate

Info

Publication number
MA31993B1
MA31993B1 MA32978A MA32978A MA31993B1 MA 31993 B1 MA31993 B1 MA 31993B1 MA 32978 A MA32978 A MA 32978A MA 32978 A MA32978 A MA 32978A MA 31993 B1 MA31993 B1 MA 31993B1
Authority
MA
Morocco
Prior art keywords
propionate
salts
medical use
trimetylhydrazinium
new medical
Prior art date
Application number
MA32978A
Other languages
Arabic (ar)
English (en)
Inventor
Ilmars Stonans
Eduard Tararak
Elena Andreyeva
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40481525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31993(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Publication of MA31993B1 publication Critical patent/MA31993B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne un nouvel usage médical des sels de 3-(2,2,2-triméthylhydrazinium) propionate pour la fabrication d'un médicament destiné à la prévention et au traitement de l'athérosclérose.
MA32978A 2007-12-04 2010-07-01 Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate MA31993B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07122273 2007-12-04
EP07122272 2007-12-04
PCT/EP2008/066711 WO2009071585A1 (fr) 2007-12-04 2008-12-03 Nouvel usage médical des sels de 3-(2,2,2-triméthylhydrazinium) propionate

Publications (1)

Publication Number Publication Date
MA31993B1 true MA31993B1 (fr) 2011-01-03

Family

ID=40481525

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32978A MA31993B1 (fr) 2007-12-04 2010-07-01 Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate

Country Status (32)

Country Link
US (1) US20100234459A1 (fr)
EP (1) EP2222293B1 (fr)
JP (1) JP2011505408A (fr)
KR (1) KR20100084688A (fr)
CN (1) CN101951898B (fr)
AR (1) AR069521A1 (fr)
AT (1) ATE518536T1 (fr)
AU (1) AU2008333262A1 (fr)
BR (1) BRPI0819057A2 (fr)
CA (1) CA2706354C (fr)
CL (1) CL2008003551A1 (fr)
CO (1) CO6280477A2 (fr)
CY (1) CY1112336T1 (fr)
DK (1) DK2222293T3 (fr)
DO (1) DOP2010000163A (fr)
EA (1) EA019424B1 (fr)
GE (1) GEP20125673B (fr)
HR (1) HRP20110744T1 (fr)
IL (1) IL205961A0 (fr)
MA (1) MA31993B1 (fr)
MX (1) MX2010006255A (fr)
MY (1) MY150508A (fr)
PA (1) PA8805901A1 (fr)
PE (1) PE20091037A1 (fr)
PL (1) PL2222293T3 (fr)
PT (1) PT2222293E (fr)
RS (1) RS51992B (fr)
SI (1) SI2222293T1 (fr)
TN (1) TN2010000250A1 (fr)
TW (1) TW200930356A (fr)
WO (1) WO2009071585A1 (fr)
ZA (1) ZA201003641B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425835A1 (fr) * 2010-08-18 2012-03-07 Grindeks, a joint stock company Nouvelle utilisation médicale de dihydrate propionate 3-(2,2,2-trimethylhydrazinium) et dérivés de flavonoïdes naturels
TWI487524B (zh) * 2010-12-03 2015-06-11 Tetra Sia 菸鹼酸和米曲肼之新穎治療組合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100745160B1 (ko) * 2003-08-04 2007-08-01 조인트 스탁 컴퍼니 그린덱스 멜도늄 염, 그것의 제조방법 및 그것을 주성분으로 한약학적 조성물

Also Published As

Publication number Publication date
EA019424B1 (ru) 2014-03-31
CL2008003551A1 (es) 2010-01-22
RS51992B (sr) 2012-04-30
CO6280477A2 (es) 2011-05-20
DK2222293T3 (da) 2011-11-21
IL205961A0 (en) 2010-11-30
CN101951898B (zh) 2012-12-05
ATE518536T1 (de) 2011-08-15
WO2009071585A1 (fr) 2009-06-11
AU2008333262A1 (en) 2009-06-11
BRPI0819057A2 (pt) 2015-05-05
CN101951898A (zh) 2011-01-19
EA201000738A1 (ru) 2011-04-29
TW200930356A (en) 2009-07-16
PT2222293E (pt) 2011-11-15
MY150508A (en) 2014-01-30
SI2222293T1 (sl) 2011-12-30
PA8805901A1 (es) 2009-07-23
CA2706354A1 (fr) 2009-06-11
ZA201003641B (en) 2011-03-30
JP2011505408A (ja) 2011-02-24
PL2222293T3 (pl) 2012-01-31
EP2222293A1 (fr) 2010-09-01
EP2222293B1 (fr) 2011-08-03
HRP20110744T1 (hr) 2011-11-30
KR20100084688A (ko) 2010-07-27
AR069521A1 (es) 2010-01-27
DOP2010000163A (es) 2010-08-31
CA2706354C (fr) 2013-08-13
TN2010000250A1 (en) 2011-11-11
PE20091037A1 (es) 2009-08-19
US20100234459A1 (en) 2010-09-16
GEP20125673B (en) 2012-10-25
MX2010006255A (es) 2011-03-15
CY1112336T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
CY1118630T1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμ1δο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
EP2193211A4 (fr) Identification de nouvelles voies pour le développement de médicaments destinés à traiter une maladie des poumons
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA200801997A1 (ru) Новые соединения
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
EP2376091A4 (fr) Nouvelles cibles pour le traitement de l'hypercholestérolémie
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
FR2902010B1 (fr) Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
FR2890865B1 (fr) Enceinte de desinfection d'instruments medicaux.
MA31993B1 (fr) Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
MA31100B1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
FR2897533B1 (fr) Agent oxydant pour le traitement des cheveux
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
MA31385B1 (fr) Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse